Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase II Evaluation of Single-Agent Bevacizumab (IND 7921) (NSC 704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC 752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma.

Next Previous
Trial Profile

A Randomized Phase II Evaluation of Single-Agent Bevacizumab (IND 7921) (NSC 704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC 752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fosbretabulin (Primary) ; Bevacizumab
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 25 Jul 2020 Results of post-hoc analysis assessing improvement in median progression free survival, published in the Gynecologic Oncology.
    • 31 Oct 2016 Post-hoc analysis results presented at meeting of the International Gynecologic Cancer Society, as per Mateon Therapeutics media release.
    • 21 Jul 2016 Status changed from active, no longer recruiting to completed, as per Mateon Therapeutics media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top